Video

Dr. Hutchings on Subgroup Analysis of ECHELON-1 in Hodgkin Lymphoma

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

Martin Hutchings, MD, PhD, staff specialist, Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, discusses a subgroup analysis of the ECHELON-1 study in Hodgkin lymphoma.

In March 2018, the FDA approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma based on findings from the phase III ECHELON-1 study. Brentuximab vedotin plus doxorubicin (Adriamycin), vinblastine, and dacarbazine (A+AVD) demonstrated superior progression-free survival (PFS) compared with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

Findings from the subgroup analysis of this study showed that when given in the frontline setting, A+AVD elicits a more favorable median PFS for patients with high-risk disease, which was defined as stage IV disease, ≥1 extranodal disease sites, or having an International Prognostic Score of 4 to 7. Results suggest that high-risk patients may derive greater benefit with A+AVD as opposed to ABVD.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD